Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15

Cortesi, Enrico; Ramponi, Sara; Corona, Mario; Moscetti, Luca; Grifalchi, Federico; Oliva, A.; Lembo, A.; Gasperoni, Silvia; Padovani, A.

doi:10.1016/s0169-5002(00)00198-7

Cited by 5 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To reduce CDDP therapy-related side effects, some combination regimens are practiced, such as combination of CDDP with palonosetron, aprepitant and dexamethasone in the emetic prophylaxis 23. To reduce CDDP therapy-related toxicities, various combination regimens are also practiced, such as combination of CDDP with gemcitabine to reduce myelotoxicities and thrombocytopenia for patients with advanced non-small-cell lung cancer and recurrent cervical cancer 24,25. The anti-tumor efficacy and tolerance remain to be the clinical issues of CDDP therapy, and some combination regimens are extensively practiced to improve the treatment status of various patients, such as combination of CDDP with vinorelbine,26 irinotecan,27 sunitinib and gemcitabine,28 as well as with gemcitabine and bevacizumab,29 for patients with advanced large-cell neuroendocrine carcinoma of the lung, for patients with advanced urothelial carcinoma, for patients with synchronous primary lung cancer and pulmonary metastatic colorectal cancer and for patients with taxane pre-treated non-small-cell lung cancer, respectively.…”

Section: Introductionmentioning

confidence: 99%

Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy

Han¹,

Zhao²,

Wang³

et al. 2016

DDDT

View full text Add to dashboard Cite

In the treatment of cancer patients, cisplatin (CDDP) exhibits serious cardiac and renal toxicities, while classical combinations related to CDDP are unable to solve these problems and may result in worse prognosis. Alternately, this study covalently conjugated 6-mercaptopurine (6MP) onto the surface of mercapto-modified mesoporous silica nanoparticles (MSNS) to form MSNS-6MP and loaded CDDP into the holes on the surface of MSNS-6MP to form MSNS-6MP/CDDP, a tumor-targeting nano-releasing regime for CDDP and 6MP specifically. In the S180 mouse model, the anti-tumor activity and overall survival of MSNS-6MP/CDDP (50 mg·kg−1·day−1, corresponding to 1 mg·kg−1·day−1 of 6MP and 5 mg·kg−1·day−1 of CDDP) were significantly higher than those of CDDP alone (5 mg·kg−1·day−1) or CDDP (5 mg·kg−1·day−1) plus 6MP (1 mg·kg−1·day−1). The assays of serum alanine aminotransferase, aspartate aminotransferase and creatinine, as well as the images of myocardium and kidney histology, support that MSNS-6MP/CDDP is able to completely eliminate liver, kidney and heart toxicities induced by CDDP alone or CDDP plus 6MP.

show abstract

Section: Introductionmentioning

confidence: 99%

Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy

Han¹,

Zhao²,

Wang³

et al. 2016

DDDT

View full text Add to dashboard Cite

show abstract

“…Studies on nonsmall cell lung cancer have shown lower bone marrow toxicity administering cisplatin on day 15 [10,11] rather than on days 1 or 2 [12].…”

Section: Discussionmentioning

confidence: 99%

Gemcitabine plus Cisplatin in Adjuvant Regimen for Bladder Cancer

Meliani¹,

Lapini²,

Serni³

et al. 2003

Urol Int

View full text Add to dashboard Cite

Objective: To evaluate the toxicity of gemcitabine and cisplatin combination therapy in adjuvant regimen after radical cystectomy for muscle invasive bladder cancer. Patients and Methods: Forty patients underwent radical cystectomy for pT2b–pT4 N0–N2 transitional cell carcinoma of the urinary bladder. They had not received prior systemic chemotherapy and were scheduled to receive gemcitabine 1,000 mg/m² on days 1, 8, and 15 and cisplatin 70 mg/m² on day 1 of a 28-day cycle, for 4 cycles. All toxicities were evaluated by World Health Organization toxicity criteria. Results: No toxic deaths occurred. All patients experienced transitory alopecia. 12/40 (30%) patients did not experience any toxicity except for alopecia. 23/40 (57.5%) had hematologic toxicity; 1/40 (2.5%) thrombocytopenia grade 4, and 3/40 (7.5%) granulocytopenia grade 3. All nonhematologic toxicities (21/40, 52.5%), including neurotoxicity, constipation and diarrhea, nausea and vomiting were less than grade 3. Conclusions: Gemcitabine plus cisplatin is a well-tolerated combination therapy with a good clinical safety profile, ethically justifiable in adjuvant regimen for bladder cancer.

show abstract

Current Awareness

2001

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15

Cited by 5 publications

References 22 publications

Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy

Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy

Gemcitabine plus Cisplatin in Adjuvant Regimen for Bladder Cancer

Current Awareness

Contact Info

Product

Resources

About